{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:19:54Z","timestamp":1791836394130,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejpb.2024.114447","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T06:13:05Z","timestamp":1723097585000},"page":"114447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Paediatric excipient risk assessment (PERA) tool and application for selecting appropriate excipients for paediatric dosage forms \u2013 Part 2"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7116-0018","authenticated-orcid":false,"given":"Anjali","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-4645","authenticated-orcid":false,"given":"Smita","family":"Salunke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Rumondor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Caivano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0804-3430","authenticated-orcid":false,"given":"Jennifer","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Enright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Sherratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3596-9228","authenticated-orcid":false,"given":"Kevin","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3075-7621","authenticated-orcid":false,"given":"David","family":"Clapham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kuehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114447_b0005","unstructured":"EMA. European Medicines Agency, Guideline on Pharmaceutical Development of Medicines for Paediatric Use. EMA; London, UK: 2013. [(accessed on 2 February 2022)]. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf. 2013."},{"key":"10.1016\/j.ejpb.2024.114447_b0010","unstructured":"FDA. Pediatric Drug Development: Regulatory Considerations \u2014 Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Available at https:\/\/www.fda.gov\/media\/168201\/download. 2023."},{"key":"10.1016\/j.ejpb.2024.114447_b0015","unstructured":"FDA. Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans Guidance for Industry.U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Available at https:\/\/www.fda.gov\/media\/86340\/download. 2020."},{"key":"10.1016\/j.ejpb.2024.114447_b0020","unstructured":"FDA. E11 Clinical Investigation of Medicinal Products in the Pediatric Population. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Available at https:\/\/www.fda.gov\/media\/71355\/download. 2000."},{"key":"10.1016\/j.ejpb.2024.114447_b0025","unstructured":"EC. Regulation (EC) no 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. 2006."},{"issue":"3","key":"10.1016\/j.ejpb.2024.114447_b0030","article-title":"Excipients in the Paediatric Population","volume":"13","author":"Rouaz","year":"2021","journal-title":"A Review. Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114447_b0035","doi-asserted-by":"crossref","unstructured":"Additives EPaneloF, Food NSat, Younes M, Aggett P, Aguilar F, Crebelli R, et al. Re-evaluation of celluloses E460(i), E460(ii), E461, E462, E463, E464, E465, E466, E468 and E469 as food additives. EFSA Journal. 2018;16(1):e05047.","DOI":"10.2903\/j.efsa.2018.5047"},{"key":"10.1016\/j.ejpb.2024.114447_b0040","unstructured":"JECFA. Powdered Cellulose. Evaluations of the Joint FAO\/WHO Expert Committee on Food Additives (JECFA). Available at https:\/\/apps.who.int\/food-additives-contaminants-jecfa-database\/Home\/Chemical\/251. 1976."},{"key":"10.1016\/j.ejpb.2024.114447_b0045","unstructured":"JECFA. Saccharin. Evaluations of the Joint FAO\/WHO Expert Committee on Food Additives (JECFA). Available at: https:\/\/apps.who.int\/food-additives-contaminants-jecfa-database\/Home\/Chemical\/3164. 1990."},{"key":"10.1016\/j.ejpb.2024.114447_b0050","unstructured":"EuPFI. Saccharin. Safety and Toxicity of Excipients in Paediatrics (STEP) database. Available at https:\/\/step-db.ucl.ac.uk\/. 2012."},{"key":"10.1016\/j.ejpb.2024.114447_b0055","unstructured":"FDA. Added Sugars on the New Nutrition Facts Label. Available at : https:\/\/www.fda.gov\/food\/new-nutrition-facts-label\/added-sugars-new-nutrition-facts-label. 2022."},{"key":"10.1016\/j.ejpb.2024.114447_b0060","unstructured":"EC. Opinion of the Scientific Committee on Food on the applicability of the ADI (Acceptable Daily Intake) for food additives to infants (expressed on 17\/09\/1998). Available at: https:\/\/food.ec.europa.eu\/system\/files\/2020-12\/sci-com_scf_out13_en.pdf. 2020."},{"key":"10.1016\/j.ejpb.2024.114447_b0065","unstructured":"Dokou E, Brodeur GG, Tauber M, Sanghvi T, Knezic D, Pesha Y, et al. High potency formulations of vx-950. WO2013116339A. Available at : https:\/\/patents.google.com\/patent\/WO2013116339A1. 2013."},{"key":"10.1016\/j.ejpb.2024.114447_b0070","unstructured":"Desai D, Diodone R, Go Z, N. P, Raman I, Iyer M, et al. Compositions and uses thereof. WO2010114928A2. Available at: https:\/\/patents.google.com\/patent\/WO2010114928A2\/en. 2010."},{"issue":"5","key":"10.1016\/j.ejpb.2024.114447_b0075","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/00016350260248292","article-title":"Betaine reduces the irritating effect of sodium lauryl sulfate on human oral mucosa in vivo","volume":"60","author":"Rantanen","year":"2002","journal-title":"Acta Odontol. Scand."},{"issue":"1","key":"10.1016\/j.ejpb.2024.114447_b0080","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijpharm.2013.09.013","article-title":"The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2 - the pilot version","volume":"457","author":"Salunke","year":"2013","journal-title":"Int J Pharm."},{"key":"10.1016\/j.ejpb.2024.114447_b0085","unstructured":"Electronic medicines compendium. Available at: https:\/\/www.medicines.org.uk\/emc#gref. 2023."},{"issue":"3","key":"10.1016\/j.ejpb.2024.114447_b0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0011-8532(22)01740-2","article-title":"The role of medication and sugars in pediatric dental patients","volume":"44","author":"Bigeard","year":"2000","journal-title":"Dent Clin North Am."},{"key":"10.1016\/j.ejpb.2024.114447_b0095","unstructured":"EMA. European Medicines Agency, Annex to the European Commission guideline on \u2018Excipients in the labelling and package leaflet of medicinal products for human use\u2019 (SANTE-2017-11668).EMA\/CHMP\/302620\/2017 Rev. 2*. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human_en-1.pdf. 2017."},{"issue":"2","key":"10.1016\/j.ejpb.2024.114447_b0100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijpharm.2017.08.051","article-title":"Use of Stevia rebaudiana purified extract as a sweetener on pediatric oral formulations","volume":"536","author":"Sep\u00falveda","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114447_b0105","unstructured":"insight F. Everything You Need to Know About Stevia Sweeteners. Food Insight Available at: https:\/\/foodinsightorg\/everything-you-need-to-know-about-stevia-sweeteners\/. 2021."},{"key":"10.1016\/j.ejpb.2024.114447_b0110","doi-asserted-by":"crossref","unstructured":"Additives EPoF, Flavourings, Younes M, Aquilina G, Engel K-H, J Fowler P, et al. Safety evaluation of glucosylated steviol glycosides as a food additive in different food categories. EFSA Journal. 2022;20(2):e07066.","DOI":"10.2903\/j.efsa.2022.7066"},{"key":"10.1016\/j.ejpb.2024.114447_b0115","unstructured":"FDA. Aspartame and Other Sweeteners in Food. Available at: https:\/\/www.fda.gov\/food\/food-additives-petitions\/aspartame-and-other-sweeteners-food. 2023."},{"issue":"5","key":"10.1016\/j.ejpb.2024.114447_b0120","first-page":"e07291","article-title":"Safety of the proposed amendment of the specifications for enzymatically produced steviol glycosides (E 960c): Rebaudioside D produced via enzymatic bioconversion of purified stevia leaf extract","volume":"20","author":"Panel EF","year":"2022","journal-title":"EFSA J."},{"key":"10.1016\/j.ejpb.2024.114447_b0125","unstructured":"EMA. European Medicines Agency, Committee for Medicinal Products for Human Use. Reflection paper: formulations of choice for the paediatric population, 2006; EMEA\/CHMP\/PEG\/194810\/2005. Available at : https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-formulations-choice-paediatric-population_en.pdf. 2006."},{"issue":"7","key":"10.1016\/j.ejpb.2024.114447_b0130","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv Drug Deliv Rev."},{"key":"10.1016\/j.ejpb.2024.114447_b0135","unstructured":"EMA. Cyclodextrins used as excipients. Report published in support of the \u2018Questions and answers on cyclodextrins used as excipients in medicinal products for human use\u2019. EMA\/CHMP\/333892\/2013. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/questions-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf. 2017."},{"key":"10.1016\/j.ejpb.2024.114447_b0140","unstructured":"EMA. Background review for cyclodextrins used as excipients. EMA\/CHMP\/333892\/2013. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/report\/background-review-cyclodextrins-used-excipients-context-revision-guideline-excipients-label-package_en.pdf. 2014."},{"key":"10.1016\/j.ejpb.2024.114447_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119396","article-title":"Sulfobutylether-\u03b2-cyclodextrin","volume":"583","author":"Stella","year":"2020","journal-title":"Int J Pharm."},{"issue":"10","key":"10.1016\/j.ejpb.2024.114447_b0150","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.fct.2005.03.007","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin (HP-\u03b2-CD): A toxicology review","volume":"43","author":"Gould","year":"2005","journal-title":"Food Chem. Toxicol."},{"issue":"8","key":"10.1016\/j.ejpb.2024.114447_b0155","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1128\/AAC.00297-07","article-title":"Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents","volume":"51","author":"Abdel-Rahman","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejpb.2024.114447_b0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","article-title":"Cyclodextrins","volume":"36","author":"Stella","year":"2008","journal-title":"Toxicol Pathol."},{"key":"10.1016\/j.ejpb.2024.114447_b0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejpb.2022.07.007","article-title":"Cyclodextrin-based delivery systems in parenteral formulations: A critical update review","volume":"178","author":"Ferreira","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112400273X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112400273X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:19:07Z","timestamp":1730092747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112400273X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"alternative-id":["S093964112400273X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114447","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paediatric excipient risk assessment (PERA) tool and application for selecting appropriate excipients for paediatric dosage forms \u2013 Part 2","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114447"}}